[Study of mumps immunity after administrating measles-mumps-rubella vaccine among children aged 2-7 years old in Jiangsu Province in 2015]

Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Jul 6;51(7):593-597. doi: 10.3760/cma.j.issn.0253-9624.2017.07.004.
[Article in Chinese]

Abstract

Objective: To investigate the immunity to mumps after administrating measles-mumps-rubella vaccine (MMR) among children aged 2-7 years old in Jiangsu province in 2015. Methods: A total of 4 190 healthy children aged 2-7 years old, living in local places for at least 3 months, and having been vaccinated at least 1 dose MMR were recruited to the study from Wujin district of Changzhou city, Gaogang district of Taizhou city and Ganyu district of Lianyungang city by using stratified cluster random sampling method between September and November, 2015. Those who did not accept MMR vaccination, who refused venous blood collection, who had affected mumps according to the memory of parents or teachers and who were diagnosed serious disease by clinical doctors were excluded from study. The self-designed questionnaire was used to collect the general information of the subjects and their MMR immunization history; and 0.5-2.0 ml of venous blood was collected from each subject. ELISA was used to detect the mumps antibody level in the serum of patients. Positive was defined as the antibody level ≥108 mU/ml, and negative as <108 mU/ml. χ(2) test was used to compare the difference in positive rates among subjects; and analysis of variance was used to compare the GMC changes in different time points after MMR vaccination. Results: Among 4 190 children, 2 280 were males (54.42%) and 1 910 were females(45.58%), and the positive rate of IgG antibody was 81.38% (3 344). There were 3 156 (95.18%) children vaccinated with one dose MMR, 187 (4.80%) children with two dose MMR, and 1 (0.02%) child with three dose MMR. The difference in positive rate of IgG antibody among different aged subjects showed statistical significance (χ(2)=58.61, P<0.001), the highest positive rate was in group of subjects aged 4-5 years old, at 89.43% (406/454), while the lowest positive rate was found among subjects aged 6-7 years old, at 75.63% (1 648/2 179). The positive rate after one dose of MMR vaccination was 79.14% (3 156/3 988), significantly less than it after two doses (93.03%, 187/201) (χ(2)=22.93, P<0.001). The GMC level at years<1, 1-<2, 2-<3, 3-<4, ≥4 following one dose MMR in the 3 988 children was 152.47, 227.78, 167.08, 126.91, 79.43 mU/ml, whose difference was statistically significant (F=51.29, P<0.001). Conclusion: The sero-prevalence of IgG antibody in the children aged 2-7 years old in Jiangsu province was high. The positive rate among who received two doses MMR was significantly higher than it among who received just one dose, and the GMC level waned with times.

目的: 分析2015年江苏2~7岁儿童接种麻疹-腮腺炎-风疹疫苗(MMR)后腮腺炎免疫水平。 方法: 于2015年9—11月,采用多阶段分层整群随机抽样方法,以常州市武进区、泰州市高港区和连云港赣榆区为研究场所,纳入年龄为2~7岁、在本地至少居住3个月及以上、身体健康并已接种至少1剂次MMR者,并排除未接种MMR、拒绝采集静脉血、经家长或老师回忆已感染过腮腺炎、经临床医生评估身体存在严重疾病或者其他原因不宜参加该研究者后,共获得4 190名调查对象。采用自行设计的调查问卷收集调查对象的基本信息及MMR免疫史;采集静脉血0.5~2.0 ml,采用ELISA法定量检测血清中腮腺抗体水平。抗体水平≥108 mU/ml为阳性,<108 mU/ml则为阴性。采用χ(2)检验比较不同特征调查对象接种MMR后腮腺炎抗体阳性率差异;采用方差分析比较调查对象仅接种1剂次MMR后不同时间GMC差异。 结果: 4 190名调查对象中,男、女分别为2 280(54.42%)和1 910(45.58%)名;腮腺炎抗体阳性率为81.38%(3 344名);接种1剂次、2剂次和3剂次MMR者分别为3 156(95.18%)、187(4.80%)和1(0.02%)名。不同年龄调查对象间腮腺炎抗体阳性率差异有统计学意义(χ(2)=58.61,P<0.001),其中4~5岁组较高,为89.43%(406/454),6~7岁组较低,为75.63%(1 648/2 179)。接种1剂次和2剂次MMR调查对象的抗体阳性率分别为79.14%(3 156/3 988)和93.03%(187/201)(χ(2)=22.93,P<0.001);3 988名调查对象仅接种1剂次MMR后<1、1~<2、2~<3、3~<4、≥4年的GMC分别为152.47、227.78、167.08、126.91、79.43 mU/ml(F=51.29,P<0.001)。 结论: 江苏2~7岁儿童腮腺炎抗体阳性率较高;接种2剂次MMR者腮腺炎抗体阳性率高于仅接种1剂次者,腮腺炎抗体GMC随着时间推移呈下降趋势。.

Keywords: Antibodies positive rate; Child; Mumps; Vaccines.

MeSH terms

  • Antibodies, Viral / blood*
  • Child
  • Child, Preschool
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Measles
  • Measles virus / immunology
  • Measles-Mumps-Rubella Vaccine / administration & dosage*
  • Measles-Mumps-Rubella Vaccine / immunology
  • Mumps / prevention & control*
  • Mumps virus / immunology*
  • Rubella virus / immunology
  • Vaccination / statistics & numerical data

Substances

  • Antibodies, Viral
  • Measles-Mumps-Rubella Vaccine